Journal of Clinical Pediatrics >
Clinical analysis of CD19/CD22 CAR-T cell therapy for MLL gene rearrangement-positive refractory/relapsed childhood acute B-lineage lymphoblastic leukemia
Received date: 2024-07-12
Online published: 2024-10-08
Objective To analyze the efficacy and safety of dual-targeted CD19/CD22 chimeric antigen receptor T-cells (CAR-T) in the treatment of refractory/relapsed B-lineage acute lymphoblastic leukemia (B-ALL) in children with MLL gene rearrangement (MLL-r). Methods The clinical data of children with MLL-r positive R/R B-ALL treated with dual-targeted CD19/CD22 CAR-T therapy between October 2019 and November 2021 were retrospectively analyzed. Results A total of 37 children (24 boys and 13 girls) with MLL-r positive R/R B-ALL were included and the median age was 1.2 (0.5-2.6) years at diagnosis, of whom 17 (45.9%) had infantile leukemia. At a median time of 9 (7-13) days after CAR-T cell infusion, 37 patients achieved a complete response rate of 100%. With a median follow-up of 28.2 (11.3 to 30.9) months, the 3-year overall survival rate was 67.6% (95% CI: 52.5 to 82.7%), and the 3-year event-free survival rate was 59.5% (95% CI: 43.6 to 75.4%).Twenty-eight patients (75.7%) underwent allogeneic hematopoietic stem cell transplantation after CAR-T cell therapy, and the median time between CAR-T infusion and transplantation was 83 (61 to 92) days. The 2-year OS for children who received consolidation grafts was 75.0% (95% CI: 58.9 to 91.1%), compared to 44.4% (95% CI 11.9 to 76.9%) for those who did not receive grafts. The difference between the two groups was not statistically significant (P=0.068). A total of 13 patients (35.1%) relapsed, and the median time from cell infusion to recurrence was 156 (86 to 202) days. Among them, 4 cases had double-positive recurrence of CD19 and CD22, 2 cases had double-negative recurrence of CD19 and CD22, 4 cases had CD19-negative recurrence, 1 case had myeloid transformation, and the other 2 cases were unclear. Cytokine release syndrome occurred in 97.3% (36/37) of patients in this study, with 29.7% (11/37) achieved grades 3 to 4. Immune effector cell-associated neurotoxicity syndrome was observed in 5 (13.5%) patients. There were no deaths due to CAR-T comorbidities.Conclusions CD19/CD22 CAR-T cell therapy is effective in inducing rapid remission in MLL-r R/R childhood B-lineage acute lymphoblastic leukemia with tolerable side effects.
Liu YANG , Meng SU , Jing ZHANG , Kang AN , Jiaoyang CAI , Juan QIAN , Yanjing TANG , Benshang LI . Clinical analysis of CD19/CD22 CAR-T cell therapy for MLL gene rearrangement-positive refractory/relapsed childhood acute B-lineage lymphoblastic leukemia[J]. Journal of Clinical Pediatrics, 2024 , 42(10) : 888 -894 . DOI: 10.12372/jcp.2024.24e0711
| [1] | Yokoyama A. Molecular mechanisms of MLL-associated leukemia[J]. Int J Hematol, 2015, 101(4): 352-361. |
| [2] | Iacobucci I, Mullighan CG. KMT2A-rearranged leukemia: the shapeshifter[J]. Blood, 2022, 140(17): 1833-1835. |
| [3] | Mann G, Attarbaschi A, Schrappe M, et al. Improved outcome with hematopoietic stem cell transplantation in a poor prognostic subgroup of infants with mixed-lineage-leukemia (MLL)-rearranged acute lymphoblastic leukemia: results from the Interfant-99 Study[J]. Blood, 2010, 116(15): 2644-2650. |
| [4] | Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial[J]. Lancet, 2015, 385(9967): 517-528. |
| [5] | Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia[J]. N Engl J Med, 2018, 378(5): 439-448. |
| [6] | Pasquini MC, Hu ZH, Curran K, et al. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma[J]. Blood Adv, 2020, 4(21): 5414-5424. |
| [7] | Majzner RG, Mackall CL. Tumor antigen escape from CAR T-cell therapy[J]. Cancer Discov, 2018, 8(10): 1219-1226. |
| [8] | Shah NN, Fry TJ. Mechanisms of resistance to CAR T cell therapy[J]. Nat Rev Clin Oncol, 2019, 16(6): 372-385. |
| [9] | Schneider D, Xiong Y, Wu D, et al. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines[J]. J Immunother Cancer, 2017, 5: 42. |
| [10] | Wang N, Hu X, Cao W, et al. Efficacy and safety of CAR19/22 T-cell cocktail therapy in patients with refractory/relapsed B-cell malignancies[J]. Blood, 2020, 135(1): 17-27. |
| [11] | Pan J, Zuo S, Deng B, et al. Sequential CD19-22 CAR T therapy induces sustained remission in children with r/r B-ALL[J]. Blood, 2020, 135(5): 387-391. |
| [12] | Brown PA, Shah B, Advani A, et al. Acute lymphoblastic leukemia, version 2.2021, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2021, 19(9): 1079-1109. |
| [13] | Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells[J]. Biol Blood Marrow Transplant, 2019, 25(4): 625-638. |
| [14] | Mahadeo KM, Khazal SJ, Abdel-Azim H, et al. Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy[J]. Nat Rev Clin Oncol, 2019, 16(1): 45-63. |
| [15] | Attarbaschi A, M?ricke A, Harrison CJ, et al. Outcomes of childhood noninfant acute lymphoblastic leukemia with 11q23/KMT2A rearrangements in a modern therapy era: a retrospective international study[J]. J Clin Oncol, 2023, 41(7): 1404-1422. |
| [16] | Pieters R, De Lorenzo P, Ancliffe P, et al. Outcome of infants younger than 1 year with acute lymphoblastic leukemia treated with the interfant-06 protocol: results from an international phase III randomized study[J]. J Clin Oncol, 2019, 37(25): 2246-2256. |
| [17] | Tomizawa D, Kato M, Takahashi H, et al. Favorable outcome in non-infant children with MLL-AF4-positive acute lymphoblastic leukemia: a report from the Tokyo Children's Cancer Study Group[J]. Int J Hematol, 2015, 102(5): 602-610. |
| [18] | Tomizawa D, Miyamura T, Imamura T, et al. A risk-stratified therapy for infants with acute lymphoblastic leukemia: a report from the JPLSG MLL-10 trial[J]. Blood, 2020, 136(16): 1813-1823. |
| [19] | Jabbour E, Short N J, Jain N, et al. The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades[J]. J Hematol Oncol, 2023, 16(1): 22. |
| [20] | Wang T, Tang Y, Cai J, et al. Coadministration of CD19- and CD22-directed chimeric antigen receptor T-Cell therapy in childhood B-cell acute lymphoblastic leukemia: a single-arm, multicenter, phase Ⅱ trial[J]. J Clin Oncol, 2023, 41(9): 1670-1683. |
| [21] | Ghorashian S, Jacoby E, De Moerloose B, et al. Tisagenlecleucel therapy for relapsed or refractory B-cell acute lymphoblastic leukaemia in infants and children younger than 3 years of age at screening: an international, multicentre, retrospective cohort study[J]. Lancet Haematol, 2022, 9(10): e766-e775. |
| [22] | Leung AW, Cai J, Wan Z, et al. Outcome of infants with acute lymphoblastic leukemia treated with the Chinese Children's Cancer Group Acute Lymphoblastic Leukemia 2015 study protocol[J]. Haematologica, 2024, 109(8): 2726-2731. |
| [23] | Yan N, Wang N, Wang G, et al. CAR19/22 T cell cocktail therapy for B-ALL relapsed after allogeneic hematopoietic stem cell transplantation[J]. Cytotherapy, 2022, 24(8): 841-849. |
| [24] | Tan X, Wang XQ, Zhang C, et al. Donor-derived CD19 CAR-T cells versus chemotherapy plus donor lymphocyte infusion for treatment of recurrent CD19-positive B-ALL after allogeneic hematopoietic stem cell transplantation[J]. Curr Med Sci, 2023, 43(4): 733-740. |
| [25] | Moskop A, Pommert L, Baggott C, et al. Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia[J]. Blood Adv, 2022, 6(14): 4251-4255. |
| [26] | Aparicio-Perez C, Carmona M, Benabdellah K, et al. Failure of ALL recognition by CAR T cells: a review of CD 19-negative relapses after anti-CD 19 CAR-T treatment in B-ALL[J]. Front Immunol, 2023, 14: 1165870. |
| [27] | Xu X, Sun Q, Liang X, et al. Mechanisms of relapse after CD19 CAR T-cell therapy for acute lymphoblastic leukemia and its prevention and treatment strategies[J]. Front Immunol, 2019, 10: 2664. |
/
| 〈 |
|
〉 |
